We are live on
!
Find out more
State Street SPDR S&P Pharmaceuticals ETF
XPH
XPH
67 hedge funds and large institutions have $109M invested in State Street SPDR S&P Pharmaceuticals ETF in 2020 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,650% more call options, than puts
Call options by funds: $3.57M | Put options by funds: $204K
11% less funds holding
Funds holding: 75 → 67 (-8)
26% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 23
36.21% less ownership
Funds ownership: 96.97% → 60.76% (-36%)
48% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 23
51% less capital invested
Capital invested by funds: $224M → $109M (-$115M)
Holders
67
Holders Change
-8
Holders Change %
-10.67%
% of All Funds
1.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
12
Reduced
23
Closed
23
Calls
$3.57M
Puts
$204K
Net Calls
+$3.37M
Net Calls Change
-$571K
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$25M |
| 2 |
Morgan Stanley
New York
|
+$20M |
| 3 |
FMP
Financial Management Professionals
Austin,
Texas
|
+$3.22M |
| 4 |
BCM
Brookstone Capital Management
Wheaton,
Illinois
|
+$2.91M |
| 5 |
SCA
Snowden Capital Advisors
New York
|
+$838K |
Top Sellers
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$56.5M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$38.8M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$23M |
| 4 |
Goldman Sachs
New York
|
-$10.5M |
| 5 |
Barclays
London,
United Kingdom
|
-$2.02M |
